This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
sclc
Small Cell Lung Cancer
Small cell lung cancer is a high-grade neuroendocrine carcinoma with near-universal RB1 and TP53 loss; atezolizumab or durvalumab + carboplatin/etoposide is first-line for extensive stage; DLL3-targeting tarlatamab is approved for relapsed disease; 5-year OS <10%.
Entry Metadata
| Field | Value |
|---|---|
| ID | sclc |
| Name | Small Cell Lung Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229. · PubMed 30280641
- Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939. · PubMed 31590988